DUBLIN--()--Research and Markets(http://www.researchandmarkets.com/research/5609ab/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Inflammatory Bowel Disease Q2 2011" report to their offering.
“Thought Leader Insight & Analysis Report - Inflammatory Bowel Disease Q2 2011”
Gastroenterology Thought Leader Panel summarizes our discussions with six internationally recognized experts in the treatment of Crohn's disease and ulcerative colitis. These took place following DDW, May 2011.
The Panel was most interested in opining on recent clinical data related to four groups of therapeutics: TNF, integrin/adhesion/MAdCAM, IL-23 and JAK. They predict the likelihood of approvals and use in the treatment of inflammatory bowel disease. Key mechanisms discussed in this report include TNF, integrin/MAdCAM, p40 (IL-23, IL-12, p19), IL-6 / JAK1 / JAK3, IL-17, CCR9 and stem cell transplant.
Key Topics Covered:
- Executive Summary
- Key Findings
- General Comments
- Tnf
- Integrin / Madcam
- P40: Anti-Il-12 / Anti-Il-23
- Jak / Syk / Il6
- Il-17
- Immunosuppressants / Immunomodulators
- Ccr9
- Steroids
- Stem Cell Transplant
- Thought-Leader Discussions
For more information visit http://www.researchandmarkets.com/research/5609ab/thought_leader_ins

